SCHEMBL6163324

SCHEMBL6163324

CC(C)(C)NS(=O)(=O)c1ccccc1-c1ccc(NC(=O)[C@H](Cc2cccc(C#N)c2)NS(C)(=O)=O)cc1

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 15/20 0.56
NAMPT P43490 2/20 0.43
F10 P00742 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6166654 0.90 USP30 (0.54) USP30
SCHEMBL6165870 0.89 F10 (0.54) USP30NAMPTF10
SCHEMBL6166435 0.89 USP30 (0.59) USP30NAMPTF10
SCHEMBL6163926 0.87 USP30 (0.57) USP30F10
SCHEMBL6163898 0.86 USP30 (0.47) USP30NAMPTF10
SCHEMBL6161572 0.84 USP30 (0.45) USP30NAMPTF10
SCHEMBL6167436 0.78 USP30 (0.55) USP30
SCHEMBL6163562 0.78 USP30 (0.55) USP30
SCHEMBL6166616 0.77 F10 (0.52) NAMPTF10
SCHEMBL6746061 0.76 USP30 (0.42) USP30NAMPTF10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI USP30 4394/4885NAMPT 348/4885F10 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.